NASDAQ NMS - GLOBAL MARKET · EWTX
+0.00% · +$0.0000 · Vol Not reported
Market closed · last close shown
Edgewise Therapeutics Inc

Edgewise Therapeutics Inc

Pharmaceuticals
$44.18
Card
Relationship Map

Veridion Score

BETALOW CONF · 4/6 factorsMethodology
Earnings absence reason unknown · Sentiment absence reason unknown
EWTX
Edgewise Therapeutics Inc
Fri Aug 21 · last completed session · Pre-market · regular session opens 9:30 ET
BUY BIAS

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

65/ 100
Veridion Score
BUY BIAS · LOW confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 4/6 factors with data · Fri Aug 21 · last completed session · Pre-market · regular session opens 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is EWTX moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading EWTX catalysts
About Edgewise Therapeutics Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2021
Employees
127
Country
US

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$44.18
Last session
Day high
$44.18
Last session
Day low
$44.18
Last session
Previous close
$44.18
52W high
$48.35
-8.62% from high
52W low
$13.70
88% of range
Market cap
$4.8B
EPS
$-1.7200
Beta
1.55
Shares out
108.6M
Avg volume
1.2M
VWAP
$44.18
Last session
Price history computed in-house
1W
+0.32%
1M
+8.18%
3M
+31.64%
1Y
+197.51%
YTD
+78.04%
SMA 50 $40.99 · above
SMA 200 $31.80 · above
52W position 88%

EWTX overview

Veridion Score
65
Registered · 2026-08-21
4 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around EWTX.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading EWTX Form 4 filings
Public disclosures

Congress activity in EWTX

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for EWTX in the cached public ledger.

Federal contracts

EWTX contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for EWTX in this window.
Lobbying spend

EWTX lobbying filings, year to date.

Registered lobbying filings matched to Edgewise Therapeutics Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for EWTX in this window.
Loading news for EWTX
Analyst ratings
Sovereign unlock shows live analyst consensus for EWTX.
Options
Sovereign unlock shows live options positioning for EWTX.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.